The Bolar exemption: the need for agreement

In recent months, we’ve had the opportunity to analyse the final decisions of the courts in Poland and Germany on the Astellas v Polpharma case interpreting the range of the Bolar exemption in Europe (for earlier details of the case click here).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

Generics

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

Generics

‘March-in’ rights: Why Biden’s changes contradict the point of Bayh-Dole

18 February 2024 While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.

More features

Baker McKenzie strengthens IP bench with new German lead

Court narrows Mylan’s Copaxone suit but key claims survive

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

EPO reports record patent filings, but pharma and biotech lag

Part I: Ozempic goes generic as Novo’s key patent expires

HSF Kramer hires patent litigator as partner in Germany

Mylan withdraws defence claims against Novo in Wegovy dispute

The Bolar exemption: the need for agreement

More on this story

Editor's picks

Editor's picks

More features